• In Q1 2026, Praxis Precision Medicines reported that the FDA accepted New Drug Applications for ulixacaltamide in essential tremor and relutrigine in developmental and epileptic encephalopathies, with target action dates set for 2027 and topline data from vormatrigine and relutrigine studies expected later in 2026.

• This combination of regulatory validation and upcoming late-stage readouts marks a pivotal moment for Praxis's central nervous system portfolio as it transitions from development toward potential commercialization.

• We'll now explore how FDA acceptance of these NDAs could reshape Praxis's earlier investment narrative built around epilepsy-focused late-stage assets.

The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Praxis Precision Medicines Investment Narrative Recap

To own Praxis today, you need to believe that its focused central nervous system pipeline can convert late stage clinical assets into real commercial products despite ongoing losses and dilution. The FDA acceptance of NDAs for ulixacaltamide and relutrigine adds validation but does not remove the near term dependence on pivotal vormatrigine epilepsy data and execution across multiple trials, which still looks like the key catalyst and the biggest operational risk over the next few years.

Among recent announcements, the FDA priority review for relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies stands out as most relevant. It directly ties into Praxis's epilepsy centric story and portfolio effect, potentially setting up an earlier regulatory decision that could sit alongside late 2026 readouts from vormatrigine and additional relutrigine studies, together shaping how concentrated or diversified the future revenue base might become.

Yet, against this backdrop of new NDAs and trial milestones, investors should still be aware of the risk that...

Read the full narrative on Praxis Precision Medicines (it's free!)

Praxis Precision Medicines' narrative projects $724.1 million revenue and $89.5 million earnings by 2029. This requires 359.5% yearly revenue growth and about a $362.5 million earnings increase from -$273.0 million today.

Uncover how Praxis Precision Medicines' forecasts yield a $449.13 fair value , a 28% upside to its current price.

Exploring Other Perspectives

Some of the lowest estimate analysts were already assuming Praxis might not reach profitability by 2028 even with revenue climbing toward about US$76.6 million, so this new FDA progress could challenge that more pessimistic view or, if setbacks emerge in the epilepsy trials, reinforce it and widen the gap between your own expectations and theirs.